Detalhe da pesquisa
1.
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
Clin Infect Dis
; 77(Suppl 4): S295-S304, 2023 10 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843115
2.
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.
Antimicrob Agents Chemother
; 66(12): e0093522, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394316
3.
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Antimicrob Agents Chemother
; 66(12): e0093622, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394326
4.
Determination of plasma protein binding of dalbavancin.
J Antimicrob Chemother
; 77(7): 1899-1902, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488862
5.
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Trials
; 23(1): 407, 2022 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35578360